Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy
Solid Biosciences received Orphan Drug Designation from the European Commission for SGT-003, its investigational gene therapy for Duchenne muscular dystrophy. The designation grants 10 years of market exclusivity in the EU upon approval and complements existing Fast Track and Rare Pediatric Disease designations in the U.S.
Key figures
- Drug Name
- SGT-003
- Phase Of Trial
- Phase 1/2 and Phase 3
- Prevalence us
- 10,000 to 15,000 cases
- Exclusivity years
- 10
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.